Overview

A Clinical Trial to Evaluate the Safety and Efficacy of Rreproxalap in Adults With Dry Eye Disease

Status:
Recruiting
Trial end date:
2022-10-01
Target enrollment:
Participant gender:
Summary
A Randomized, Double-Masked, Vehicle-Controlled Crossover Clinical Trial to Assess Efficacy and Safety of 0.25% Reproxalap Ophthalmic Solution Compared to Vehicle in Subjects with Dry Eye Disease
Phase:
Phase 2
Details
Lead Sponsor:
Aldeyra Therapeutics, Inc.
Treatments:
Ophthalmic Solutions
Pharmaceutical Solutions